

THE CLINICAL THERAPEUTICS OF PRESCRIBING: BRIDGING PHARMACOLOGICAL KNOWLEDGE AND PATIENT-CENTERED OUTCOMES

Sanaqaulova Yulduz

Scientific supervisor: Asatullayev Rustamjon Bakhtiyarovich

Trainee assistant at Samarkand state medical university

ARTICLE INFORMATION

ABSTRACT:

ARTICLE HISTORY:

Received:05.05.2026

Revised: 06.05.2026

Accepted:07.05.2026

KEYWORDS:

clinical therapeutics, prescribing, pharmacology, rational drug use, medication safety, therapeutic outcomes, individualized treatment, evidence-based medicine

Clinical therapeutics of prescribing is a core domain of modern healthcare that connects pharmacological science with individualized patient care. Prescribing is not merely the selection of a medicine for a diagnosed disease; rather, it is a deliberate, evidence-informed, and patient-centered process that integrates pharmacodynamics, pharmacokinetics, therapeutic goals, patient characteristics, comorbidities, safety considerations, adherence patterns, and ethical responsibility. In contemporary practice, clinicians are expected to move beyond disease-oriented treatment algorithms and consider how medications influence quality of life, functional outcomes, and long-term wellbeing. The article also highlights the challenges posed by multimorbidity, antimicrobial resistance, adverse drug reactions, and health inequities in access to medicines. Ultimately, effective prescribing requires not only scientific competence but also clinical judgment, communication skills, and a commitment to optimizing outcomes that matter to patients.

The clinical act of prescribing occupies a central place in healthcare because it is one of the most direct ways clinicians influence patient outcomes. Every prescription reflects a chain

of decisions involving diagnosis, pathophysiology, drug selection, dose determination, route of administration, treatment duration, and monitoring strategy. Yet prescribing is not simply a technical act grounded in pharmacological facts; it is a therapeutic intervention that must be adapted to the person receiving it. In this sense, clinical therapeutics of prescribing represents the bridge between biomedical science and humane care. It links what is known about medicines with what is needed by patients in real-world clinical contexts.

Pharmacology provides the scientific foundation for prescribing. It explains how drugs interact with receptors, enzymes, ion channels, transporters, and signaling pathways to produce desired therapeutic effects as well as unintended adverse consequences. Pharmacodynamics helps clinicians understand what a drug does to the body, while pharmacokinetics clarifies what the body does to the drug through absorption, distribution, metabolism, and excretion. These principles are indispensable when selecting medications for conditions such as hypertension, diabetes mellitus, asthma, infectious disease, pain, psychiatric illness, or cardiovascular disorders. However, pharmacological knowledge alone does not ensure good prescribing. The same medicine may be highly effective in one patient and ineffective or harmful in another due to age, genetics, organ function, nutritional status, coexisting disease, or concomitant medications.

This is why rational prescribing has emerged as a defining principle of modern therapeutics. Rational prescribing means choosing the right medicine for the right patient at the right dose for the right duration and for the right indication. It requires clinicians to balance efficacy, safety, convenience, affordability, and acceptability. A rational prescription is not necessarily the newest or most expensive treatment; rather, it is the one most likely to achieve clinically meaningful benefit with the least avoidable harm. Rational prescribing also involves restraint. Not every symptom requires a medicine, and not every diagnosis warrants immediate pharmacological intervention. In some cases, watchful waiting, lifestyle modification, counseling, or non-pharmacological therapy may provide better long-term outcomes than unnecessary medication use.

One of the most important developments in therapeutics has been the shift from disease-centred to patient-centred prescribing. Disease-centred prescribing focuses primarily on achieving biomedical targets such as blood pressure levels, glycaemic control, cholesterol reduction, or infection eradication. While these are important, patient-centred prescribing asks additional questions: Does the treatment align with the patient's values? Can the patient adhere to the regimen? Does it improve symptoms, functioning, independence, and quality of life? Is the burden of treatment acceptable? This approach recognizes that the "best" medicine

on paper may not be the best medicine in practice if it is poorly tolerated, unaffordable, culturally unacceptable, or incompatible with the patient's daily life.

Patient-centred outcomes are especially important in chronic disease management. In conditions such as diabetes, hypertension, heart failure, epilepsy, depression, and rheumatoid arthritis, medicines are often taken for months or years rather than days. The success of therapy therefore depends not only on pharmacological potency but also on persistence, adherence, tolerability, and patient understanding. A once-daily regimen may be more effective in practice than a more pharmacologically elegant but complex schedule that the patient cannot sustain. Similarly, a drug with a slightly lower efficacy profile may be the more appropriate option if it causes fewer adverse effects, requires less laboratory monitoring, or better fits the patient's financial capacity.

The concept of individualized prescribing is particularly relevant in this context. No two patients are identical, and the therapeutic response to medications is influenced by a wide range of biological and contextual factors. Age is a major determinant of drug response. In children, developmental physiology alters drug absorption and metabolism, requiring careful dose adjustments. In older adults, changes in renal clearance, hepatic metabolism, body composition, and receptor sensitivity increase susceptibility to adverse drug reactions. Geriatric prescribing therefore demands particular caution, especially with sedatives, anticholinergics, anticoagulants, opioids, and antihypertensives. Prescribers must remain aware that older patients often have multiple chronic illnesses and are exposed to polypharmacy, increasing the risk of drug-drug interactions and prescribing cascades.

Comorbidity further complicates therapeutic decision-making. A medicine recommended for one condition may worsen another. Non-steroidal anti-inflammatory drugs may relieve musculoskeletal pain but exacerbate hypertension, chronic kidney disease, or peptic ulcer disease. Beta-blockers may benefit ischemic heart disease yet require caution in patients with asthma. Corticosteroids may rapidly control inflammatory conditions but worsen glycaemic control and contribute to osteoporosis or infection risk. Effective prescribing therefore demands a whole-patient perspective rather than a narrow disease-specific approach. The clinician must constantly weigh therapeutic gain against systemic impact.

Medication safety is another fundamental pillar of clinical therapeutics. Prescribing errors, dosing mistakes, illegible instructions, overlooked contraindications, and inadequate monitoring can all lead to preventable harm. Adverse drug reactions remain a major source of hospital admissions and morbidity worldwide. Some adverse reactions are predictable extensions of pharmacological action, such as bleeding with anticoagulants or hypoglycaemia

with insulin and sulfonylureas. Others are idiosyncratic, immune-mediated, or genetically influenced. Safe prescribing requires vigilance at every stage: reviewing allergies, checking organ function, considering pregnancy or lactation, assessing interaction potential, educating patients about warning signs, and planning appropriate follow-up.

Polypharmacy is one of the greatest therapeutic challenges in modern medicine, especially among elderly and medically complex patients. While the use of multiple medicines may be clinically justified, it also increases the risk of interactions, duplication, non-adherence, confusion, and cumulative toxicity. Polypharmacy is not merely a numerical issue; its significance lies in whether the overall regimen remains appropriate, coherent, and beneficial. A patient taking ten carefully justified medications with clear benefit may be better managed than a patient taking four poorly indicated ones. Therefore, the clinical therapeutics of prescribing must include regular medication review, reconciliation, and deprescribing where appropriate. Deprescribing is not therapeutic neglect; it is a proactive strategy to reduce harm and simplify treatment while preserving essential benefit.

Antimicrobial prescribing deserves special attention because it involves both individual and public health consequences. The inappropriate use of antibiotics contributes to antimicrobial resistance, a major global threat. Clinical therapeutics in this area requires careful diagnostic reasoning, appropriate empiric selection, timely de-escalation based on culture results, correct duration of therapy, and stewardship awareness. Prescribers must resist patient or institutional pressures that encourage unnecessary antibiotic use for viral or self-limiting illnesses. Here, the bridge between pharmacological knowledge and patient-centred outcomes extends beyond the individual to the wider community.

In conclusion, prescribing is one of the most powerful and complex therapeutic tools in clinical practice. Its success depends on the ability to integrate pharmacological principles with individualized, evidence-based, and patient-centred care. Effective prescribing requires far more than selecting a drug from a guideline; it involves balancing efficacy with safety, science with context, and disease control with patient priorities. As healthcare becomes increasingly complex, the future of clinical therapeutics will depend on prescribers who can bridge knowledge and humanity in every prescription they write.

References

1. De Vries, T. P. G. M., Henning, R. H., Hogerzeil, H. V., & Fresle, D. A. Guide to Good Prescribing: A Practical Manual. Geneva: World Health Organization, 1994.

-
2. World Health Organization. Medication Without Harm. Geneva: WHO, 2017.
 3. World Health Organization. Medication Without Harm: Policy Brief. Geneva: WHO, 2024.
 4. National Institute for Health and Care Excellence (NICE). Medicines Optimisation: The Safe and Effective Use of Medicines to Enable the Best Possible Outcomes. London: NICE Guideline NG5, 2015.
 5. Reeve, E., Gnjjidic, D., Long, J., & Hilmer, S. A Narrative Review of Evidence to Guide Deprescribing Among Older Adults. *British Journal of Clinical Pharmacology*, 2021.
 6. Ailabouni, N. J., Nishtala, P. S., & Mangin, D. Review of Structured Guides for Deprescribing. *European Journal of Hospital Pharmacy*, 2019.
 7. Scott, I. A., Hilmer, S. N., Reeve, E., Potter, K., Le Couteur, D., Rigby, D., et al. Deprescribing in Older People. *Australian Prescriber*, 2019.
 8. Lee, A. M., Smith, P. G., et al. Deprescribing in Community-Dwelling Older Adults: A Systematic Review and Meta-Analysis. *JAMA Network Open*, 2025.
 9. Gilmartin-Thomas, J. F. M., et al. Deprescribing Interventions in Older Adults: An Overview of Systematic Reviews. *Age and Ageing*, 2024.
 10. Rankin, A., Cadogan, C. A., Patterson, S. M., et al. Interventions to Improve the Appropriate Use of Polypharmacy for Older People. *Cochrane Database of Systematic Reviews*, 2018.